In patients with a history of myocardial infarction (MI), SGLT2 inhibitors have been shown to reduce major adverse cardiovascular events (MACEs) and hospitalization for HF (HHF) among those with T2DM [11, 12]. Here, SLC5A2 is linked to myocardial infarction.